Sitagliptin/Metformin "Orion" 50+1000 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sitagliptin/metformin "orion" 50+1000 mg filmovertrukne tabletter

orion corporation - metforminhydrochlorid, sitagliptinhydrochloridmonohydrat - filmovertrukne tabletter - 50+1000 mg

Sitagliptin/Metformin "Stada" 50+1000 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sitagliptin/metformin "stada" 50+1000 mg filmovertrukne tabletter

stada arzneimittel ag - metforminhydrochlorid, sitagliptinhydrochlorid - filmovertrukne tabletter - 50+1000 mg

Sitagliptin/Metformin "Grindeks" 50+1000 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sitagliptin/metformin "grindeks" 50+1000 mg filmovertrukne tabletter

as grindeks - metforminhydrochlorid, sitagliptinhydrochloridmonohydrat - filmovertrukne tabletter - 50+1000 mg

Sitagliptin/Metformin "Reddy" 50+1000 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sitagliptin/metformin "reddy" 50+1000 mg filmovertrukne tabletter

reddy holding gmbh - metforminhydrochlorid, sitagliptinhydrochloridmonohydrat - filmovertrukne tabletter - 50+1000 mg

Eucreas Den Europæiske Union - dansk - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Zomarist Den Europæiske Union - dansk - EMA (European Medicines Agency)

zomarist

novartis europharm limited  - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Segluromet Den Europæiske Union - dansk - EMA (European Medicines Agency)

segluromet

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Jentadueto Den Europæiske Union - dansk - EMA (European Medicines Agency)

jentadueto

boehringer ingelheim international gmbh - linagliptin, metformin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - behandling af voksne patienter med type-2-diabetes mellitus:jentadueto er indiceret som et supplement til kost og motion til forbedring af glykæmisk kontrol hos voksne patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin alene, eller dem, der allerede behandles med en kombination af linagliptin og metformin. jentadueto er indiceret i kombination med sulphonylurea (jeg. triple kombinationsbehandling) som supplement til diæt og motion hos voksne patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea.

Synjardy Den Europæiske Union - dansk - EMA (European Medicines Agency)

synjardy

boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - synjardy er indiceret hos voksne i alderen 18 år og ældre med type 2-diabetes som et supplement til kost og motion til forbedring af glykæmisk kontrol:patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimalt tolereret dosis af metformin alene, patienter, der ikke er tilstrækkeligt kontrolleret med metformin i kombination med andre glukose-sænkende lægemidler, herunder insulin;hos patienter, der allerede behandles med en kombination af empagliflozin og metformin som særskilte tabletter.

Vildagliptin/Metformin "Stada" 50+1000 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

vildagliptin/metformin "stada" 50+1000 mg filmovertrukne tabletter

stada arzneimittel ag - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+1000 mg